Outset Medical Reports Fourth Quarter and Full Year 2024 Financial Results

Rhea-AI Summary

Outset Medical (Nasdaq: OM) reported Q4 and full-year 2024 financial results, exceeding prior guidance. Q4 net revenue reached $29.5 million, with full-year revenue at $113.7 million. The company achieved significant gross margin improvements, reaching 36.5% in Q4 (37.7% non-GAAP), up 11 percentage points year-over-year.

The Tablo installed base grew 10% in 2024 to nearly 6,000 consoles. Recurring revenue from Tablo consumables and services increased 21% to $83.9 million for the full year. The company's net loss improved to $128 million ($2.46 per share) in 2024, compared to $172.8 million in 2023.

Following a January 2025 financing, Outset's cash position strengthened to approximately $210 million. The company provided 2025 revenue guidance of $115-125 million with expected non-GAAP gross margins in the high-30% range, projecting to use less than $50 million cash in 2025.

Positive

• Gross margin improved significantly to 36.5% in Q4 2024, up 11 percentage points YoY
• Recurring revenue grew 21% to $83.9 million in 2024
• Tablo installed base increased 10% to nearly 6,000 consoles
• Operating expenses reduced by 28% YoY in Q4 2024
• Cash burn expected to decrease from $103M in 2024 to less than $50M in 2025

Negative

• Full-year revenue declined 13% to $113.7M in 2024 compared to $130.4M in 2023
• Q4 revenue decreased 3% YoY to $29.5M
• Net loss of $128M in 2024, though improved from 2023
• Product revenue declined 22% to $81M in 2024

Insights

Financial Analyst

The Q4 and FY2024 results reveal Outset Medical's strategic pivot toward operational efficiency and sustainable growth. The standout metric is the 17% YoY growth in Q4 recurring revenue to $23.7M, representing 80% of total revenue - a important indicator of business stability and scalability in the medical technology sector.

Three key developments signal a fundamental improvement in the business model:

• Gross margin expansion of 1,120 basis points YoY to 36.5% in Q4, driven by manufacturing optimization and economies of scale
• Operating expense reduction of 28% YoY while maintaining 10% growth in installed base, indicating improved operational leverage
• Projected cash burn reduction from $103M in 2024 to below $50M in 2025, suggesting accelerated path to profitability

The 2025 guidance of $115-125M in revenue with high-30% gross margins reflects management's confidence in the commercial transformation and operational improvements. The recent financing securing $210M in cash provides adequate runway through cash flow breakeven, significantly de-risking the execution path.

The 21% growth in full-year recurring revenue to $83.9M demonstrates strong product adoption and customer retention, particularly important in the dialysis market where consistent utilization drives long-term value. The expanding Tablo installed base of nearly 6,000 consoles creates a robust foundation for future recurring revenue growth.

SAN JOSE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2024.

Fourth Quarter, Year-End Highlights

• Net revenue of $29.5 million in the fourth quarter and $113.7 million in 2024 were both ahead of the company’s prior guidance and preannouncement in January.
• Gross margin of 36.5% (37.7% on a non-GAAP basis) in the fourth quarter increased 220 basis points sequentially from the third quarter and 11 percentage points from the fourth quarter of 2023. Gross margin for the full year was 33.9% (35.6% on a non-GAAP basis) compared to 22.2% (23.7% on a non-GAAP basis) in 2023.
• The Tablo installed base reached nearly 6,000 consoles, growing 10% in 2024.
• Recurring revenue consisting of Tablo consumables and services, grew 13% sequentially from the third quarter, 17% over the prior-year period, and 21% to $83.9 million for full-year 2024.

“We enter 2025 with positive momentum, having delivered two solid quarters under our transforming commercial organization,” said Leslie Trigg, Chair and Chief Executive Officer. “Strong utilization across our Tablo installed base drove another record quarter of recurring revenue, and our strengthened balance sheet positions us through cash flow breakeven. Our team remains focused on the opportunities ahead—supporting customers, restoring well-being to people with end-stage renal disease and driving meaningful growth." 

Fourth Quarter 2024 Financial Results

Revenue for the fourth quarter was $29.5 million, an increase of 3% compared to $28.7 million in the third quarter and a decrease of 3% compared to $30.5 million in the fourth quarter of 2023. Product revenue of $21 million rose 3% from $20.3 million in the third quarter and declined 8% from $22.9 million in the fourth quarter of 2023. Service and other revenue was $8.5 million, roughly even with $8.4 million reported in the third quarter and representing an increase of 11% compared to $7.6 million in the fourth quarter of 2023. Recurring revenue from the sale of Tablo cartridges and service reached $23.7 million, an increase of 13% from $21 million in the third quarter and 17% as compared to $20.2 million in the prior-year period.

Total gross profit of $10.7 million increased 9% from the third quarter and 39% from $7.7 million for the fourth quarter of 2023. Total gross margin was 36.5%, compared to 34.3% in the third quarter and 25.3% in the fourth quarter of 2023. On a non-GAAP basis, gross margin improved to 37.7% from 36.4% in the third quarter and 27.1% in the fourth quarter of 2023. Product gross profit was $9.2 million, compared to $8.3 million in the fourth quarter of 2023. Product gross margin was 44%, compared to 36.3% in the fourth quarter of 2023. Service and other gross profit was $1.5 million, compared to a loss of $0.6 million in the fourth quarter of 2023. Service and other gross margin was 17.8%, compared to (7.8%) in the fourth quarter of 2023.

Operating expenses of $32.6 million declined 28% from the prior-year period as a result of reductions in spending during the year intended to streamline operations and accelerate the company’s path to profitability. Research and development (R&D) expenses were $7.9 million, sales and marketing (S&M) expenses were $15.5 million, and general and administrative (G&A) expenses were $9.3 million. This compared to operating expenses of $45.1 million in the fourth quarter of 2023, including R&D expenses of $12.5 million, S&M expenses of $22.2 million, and G&A expenses of $10.3 million.

Excluding stock-based compensation expense and severance and related charges, net of adjustments to compensation accrual, non-GAAP operating expenses were $26.6 million, including R&D expenses of $5.8 million, S&M expenses of $14.0 million, and G&A expenses of $6.8 million.

Net loss was $25.6 million, or ($0.49) per share, compared to net loss of $38.6 million, or ($0.77) per share, for the same period in 2023. On a non-GAAP basis, net loss was $19.3 million, or ($0.37) per share, compared to non-GAAP net loss of $27 million, or ($0.54) per share for the same period in 2023.

Total cash, including restricted cash, cash equivalents and short-term investments, was $162 million as of December 31, 2024, compared to $206.7 million as of December 31, 2023. Following the closing of a financing announced on January 6, 2025, the company had approximately $210 million in cash, including restricted cash, cash equivalents and short-term investments.

Full Year 2024 Financial Results

Revenue for 2024 of $113.7 million was ahead of the company’s prior guidance, and a decline of 13% as compared to $130.4 million in 2023. Product revenue was $81 million, representing a decrease of 22% compared to $103.5 million in 2023. Service and other revenue was $32.7 million, an increase of 22% compared to $26.8 million in 2023. Recurring revenue grew 21% to $83.9 million compared to $69 million in 2023.

Total gross profit was $38.6 million, compared to $29 million for 2023. Total gross margin was 33.9%, compared to 22.2% in 2023. On a non-GAAP basis, gross margin improved nearly 12 percentage points to 35.6% from 23.7% in 2023. Product gross profit was $34.5 million, compared to $29.1 million in 2023. Product gross margin was 42.6%, compared to 28.1% in 2023. Service and other gross profit was $4 million, compared to a loss of $0.1 million in 2023. Service and other gross margin was 12.3%, compared to (0.3%) in 2023.

Operating expenses were $151.9 million, including R&D expenses of $38.4 million, S&M expenses of $70 million, and G&A expenses of $43.5 million. This compared to operating expenses of $198.8 million, including R&D expenses of $57.3 million, S&M expenses of $96.2 million, and G&A expenses of $45.2 million in 2023.

Excluding stock-based compensation expense and severance and related charges, net of adjustments to compensation accrual, non-GAAP operating expenses were $119.3 million, including R&D expenses of $29.1 million, S&M expenses of $61.9 million, and G&A expenses of $28.3 million.

Net loss was $128 million, or ($2.46) per share, compared to a net loss of $172.8 million, or ($3.48) per share, in 2023. On a non-GAAP basis, net loss was $93.4 million, or ($1.79) per share, compared to a non-GAAP net loss of $131.6 million, or ($2.65) per share in 2023.

Full Year 2025 Financial Guidance

Outset provided 2025 revenue guidance of $115 million to $125 million, and non-GAAP gross margin guidance in the high-30% range. Additionally, the company expects to use less than $50 million of cash in 2025 as compared to the $103 million used in 2024.

Webcast and Conference Call Details

Outset will host a conference call today, February 19, 2025, at 2:00 p.m. PT / 5:00 p.m. ET to discuss its fourth quarter and full year 2024 financial results. Those interested in listening to the conference call may do so by registering online. Once registered, participants will receive dial-in numbers and a unique pin to join the call. Participants are encouraged to register more than 15 minutes before the start of the call. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at https://investors.outsetmedical.com. The webcast will be archived on the website following the completion of the call.

Use of Non-GAAP Financial Measures

The Company may report non-GAAP results for gross profit/loss, gross margin, operating expenses, operating margins, net income/loss, basic and diluted net income/loss per share, other income/loss, and cash flows. These non-GAAP financial measures are in addition to, and not a substitute for, or superior to, financial measures calculated in accordance with GAAP. As listed in the itemized reconciliations between GAAP and non-GAAP financial measures included in this press release, the Company’s GAAP financial measures include stock-based compensation expense, as well as severance and related charges net of the reversal of compensation accruals for impacted employees. Stock-based compensation is a non-cash expense, and severance and related charges arise outside the ordinary course of continuing operations and are not reflective of the Company's current operating performance. As such, management has excluded the effects of these items in non-GAAP measures to assist investors in analyzing and assessing past and future operating performance and period-to-period comparisons. There are limitations related to the use of non-GAAP financial measures because they are not prepared in accordance with GAAP, may exclude significant expenses required by GAAP to be recognized in the Company’s financial statements, and may not be comparable to non-GAAP financial measures used by other companies. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP results are presented in the Appendix A of this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the Company’s possible or assumed future results of operations and financial position, including expectations regarding projected revenues, gross margin, operating expenses, capital expenditures, cash burn, cash position, profitability and outlook;  statements about anticipated benefits of the Company’s recent financing activities, including its expectations that the funds will capitalize it through cashflow breakeven; statements regarding the anticipated impacts and benefits of the Company’s cost reduction actions, initiatives to optimize the commercial organization and restructurings; statements regarding the Company’s overall business strategy, plans and objectives of management; the Company’s expectations regarding the market sizes and growth potential for Tablo and the total addressable market opportunities for Tablo; continued execution of the Company’s initiatives designed to expand gross margins; the Company’s ability to respond to and resolve any reports, observations or other actions by the Food and Drug Administration or other regulators in a timely and effective manner; as well as the Company’s expectations regarding the impact of macroeconomic factors on the Company, its customers and suppliers. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of the Company’s public filings with the Securities and Exchange Commission, including its latest annual and quarterly reports. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

About Outset Medical, Inc.

Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.

Investor Contact
Jim Mazzola
jmazzola@outsetmedical.com

Outset Medical, Inc. Condensed Statements of Operations (in thousands, except per share amounts) (unaudited)
		Three Months Ended										Years Ended
		December 31,										December 31,
		2024					2023					2024					2023
Revenue:
Product revenue		$	21,006				$	22,897				$	80,977				$	103,537
Service and other revenue			8,461					7,610					32,712					26,839
Total revenue			29,467					30,507					113,689					130,376
Cost of revenue:
Cost of product revenue (2)			11,769					14,588					46,449					74,454
Cost of service and other revenue			6,951					8,207					28,676					26,922
Total cost of revenue			18,720					22,795					75,125					101,376
Gross profit (1)			10,747					7,712					38,564					29,000
Gross margin (1)			36.5		%			25.3		%			33.9		%			22.2		%
Operating expenses:
Research and development (2)			7,889					12,532					38,397					57,307
Sales and marketing (2)			15,451					22,194					70,044					96,232
General and administrative (2)			9,267					10,339					43,498					45,231
Total operating expenses			32,607					45,065					151,939					198,770
Loss from operations			(21,860	)				(37,353	)				(113,375	)				(169,770	)
Interest income and other income, net			2,043					2,282					9,761					10,171
Interest expense			(5,825	)				(3,417	)				(23,871	)				(12,675	)
Loss before provision for income taxes			(25,642	)				(38,488	)				(127,485	)				(172,274	)
Provision for income taxes			(4	)				112					491					523
Net loss		$	(25,638	)			$	(38,600	)			$	(127,976	)			$	(172,797	)
Net loss per share, basic and diluted		$	(0.49	)			$	(0.77	)			$	(2.46	)			$	(3.48	)
Shares used in computing net loss per share, basic and diluted			52,742					50,254					51,951					49,588

(1) Gross profit and gross margin by source consisted of the following:
		Three Months Ended										Years Ended
		December 31,										December 31,
		2024					2023					2024					2023
Gross profit
Product revenue		$	9,237				$	8,309				$	34,528				$	29,083
Service and other revenue			1,510					(597	)				4,036					(83	)
Total gross profit		$	10,747				$	7,712				$	38,564				$	29,000
Gross margin
Product revenue			44.0		%			36.3		%			42.6		%			28.1		%
Service and other revenue			17.8		%			(7.8	)	%			12.3		%			(0.3	)	%
Total gross margin			36.5		%			25.3		%			33.9		%			22.2		%
(2) Includes stock-based compensation expense and severance and related charges, net as follows:
		Three Months Ended										Years Ended
Stock-based compensation expense		December 31,										December 31,
		2024					2023					2024					2023
Cost of revenue		$	280				$	424				$	1,372				$	1,805
Research and development			1,266					2,306					7,291					10,538
Sales and marketing			1,224					2,511					6,122					12,419
General and administrative			2,175					3,857					14,571					13,872
Total stock-based compensation expense		$	4,945				$	9,098				$	29,356				$	38,634
		Three Months Ended										Years Ended
Severance and related charges, net*		December 31,										December 31,
		2024					2023					2024					2023
Cost of revenue		$	49					129				$	567					129
Research and development			847					739					1,971					739
Sales and marketing			265					1,294					2,030					1,294
General and administrative			245					370					635					370
Total severance and related charges, net		$	1,406					2,532				$	5,203					2,532
* Net of adjustments to compensation accrual

Outset Medical, Inc. Condensed Balance Sheets (in thousands, except per share amounts)
		December 31,
		2024				2023
		(Unaudited)
Assets
Current assets:
Cash and cash equivalents		$	124,014			$	68,509
Short-term investments			34,671				134,815
Accounts receivable, net			35,619				32,980
Inventories			59,387				49,215
Prepaid expenses and other current assets			4,530				5,700
Total current assets			258,221				291,219
Restricted cash			3,329				3,329
Property and equipment, net			8,133				13,273
Operating lease right-of-use assets			3,940				5,375
Other assets			2,172				605
Total assets		$	275,795			$	313,801
Liabilities and stockholders' equity
Current liabilities:
Accounts payable		$	3,862			$	5,827
Accrued compensation and related benefits			16,821				19,005
Accrued expenses and other current liabilities			8,205				13,459
Accrued warranty liability			1,938				3,712
Deferred revenue, current			12,753				11,727
Operating lease liabilities, current			1,799				1,593
Total current liabilities			45,378				55,323
Accrued interest			2,695				896
Deferred revenue			844				101
Operating lease liabilities			2,684				4,482
Term loans			197,375				130,113
Total liabilities			248,976				190,915
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of December 31, 2024 and 2023			—				—
Common stock, $0.001 par value; 300,000 shares authorized as of December 31, 2024 and December 31, 2023; 52,944 and 50,317 shares issued and outstanding as of December 31, 2024 and 2023, respectively			53				50
Additional paid-in capital			1,116,447				1,084,515
Accumulated other comprehensive income			42				68
Accumulated deficit			(1,089,723	)			(961,747	)
Total stockholders' equity			26,819				122,886
Total liabilities and stockholders' equity		$	275,795			$	313,801

Outset Medical, Inc. Condensed Statements of Cash Flows (in thousands) (unaudited)
		Years Ended December 31,
		2024				2023
Net cash used in operating activities		$	(116,303	)		$	(131,373	)
Net cash provided by investing activities			103,938				83,026
Net cash provided by financing activities			67,870				43,652
Net increase (decrease) in cash, cash equivalents and restricted cash			55,505				(4,695	)
Cash, cash equivalents and restricted cash at beginning of the period			71,838				76,533
Cash, cash equivalents and restricted cash at end of the period (1)		$	127,343			$	71,838
(1) The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed balance sheets that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands):
		December 31,
		2024				2023
Cash and cash equivalents		$	124,014			$	68,509
Restricted cash			3,329				3,329
Total cash, cash equivalents and restricted cash*		$	127,343			$	71,838
* The total cash, including restricted cash, cash equivalents and investment securities as of December 31, 2024 was $162.0 million; compared to $206.7 million as of December 31, 2023.

Appendix A

Outset Medical, Inc. Results of Operations – Non-GAAP (in thousands, except per share amounts) (unaudited)
Reconciliation between GAAP and non-GAAP net loss per share:
		Three Months Ended										Years Ended
		December 31,										December 31,
		2024					2023					2024					2023
GAAP net loss per share, diluted		$	(0.49	)			$	(0.77	)			$	(2.46	)			$	(3.48	)
Stock-based compensation expense			0.09					0.18					0.57					0.78
Severance and related charges, net			0.03					0.05					0.10					0.05
Non-GAAP net loss per share, diluted		$	(0.37	)			$	(0.54	)			$	(1.79	)			$	(2.65	)
Reconciliation between GAAP and non-GAAP net loss:
		Three Months Ended										Years Ended
		December 31,										December 31,
		2024					2023					2024					2023
GAAP net loss, diluted		$	(25,638	)			$	(38,600	)			$	(127,976	)			$	(172,797	)
Stock-based compensation expense			4,945					9,098					29,356					38,634
Severance and related charges, net			1,406					2,532					5,203					2,532
Non-GAAP net loss, diluted		$	(19,287	)			$	(26,970	)			$	(93,417	)			$	(131,631	)
Reconciliation between GAAP and non-GAAP results of operations:
		Three Months Ended										Years Ended
		December 31,										December 31,
		2024					2023					2024					2023
GAAP gross profit		$	10,747				$	7,712				$	38,564				$	29,000
Stock-based compensation expense			280					424					1,372					1,805
Severance and related charges, net			49					129					567					129
Non-GAAP gross profit		$	11,076				$	8,265				$	40,503				$	30,934
GAAP gross margin			36.5		%			25.3		%			33.9		%			22.2		%
Stock-based compensation expense			1.0					1.4					1.2					1.4
Severance and related charges, net			0.2					0.4					0.5					0.1
Non-GAAP gross margin			37.7		%			27.1		%			35.6		%			23.7		%
GAAP research and development expense		$	7,889				$	12,532				$	38,397				$	57,307
Stock-based compensation expense			(1,266	)				(2,306	)				(7,291	)				(10,538	)
Severance and related charges, net			(847	)				(739	)				(1,971	)				(739	)
Non-GAAP research and development expense		$	5,776				$	9,487				$	29,135				$	46,030
GAAP sales and marketing expense		$	15,451				$	22,194				$	70,044				$	96,232
Stock-based compensation expense			(1,224	)				(2,511	)				(6,122	)				(12,419	)
Severance and related charges, net			(265	)				(1,294	)				(2,030	)				(1,294	)
Non-GAAP sales and marketing expense		$	13,962				$	18,389				$	61,892				$	82,519
GAAP general and administrative expense		$	9,267				$	10,339				$	43,498				$	45,231
Stock-based compensation expense			(2,175	)				(3,857	)				(14,571	)				(13,872	)
Severance and related charges, net			(245	)				(370	)				(635	)				(370	)
Non-GAAP general and administrative expense		$	6,847				$	6,112				$	28,292				$	30,989
GAAP total operating expense		$	32,607				$	45,065				$	151,939				$	198,770
Stock-based compensation expense			(4,665	)				(8,674	)				(27,984	)				(36,829	)
Severance and related charges, net			(1,357	)				(2,403	)				(4,636	)				(2,403	)
Non-GAAP total operating expense		$	26,585				$	33,988				$	119,319				$	159,538

FAQ

What was Outset Medical's (OM) revenue guidance for 2025?

Outset Medical provided 2025 revenue guidance of $115 million to $125 million, with non-GAAP gross margin expected in the high-30% range.

How much did Outset Medical's (OM) recurring revenue grow in 2024?

Outset Medical's recurring revenue grew 21% to $83.9 million in 2024 compared to $69 million in 2023.

What was Outset Medical's (OM) cash position at the end of 2024?

Following a January 2025 financing, Outset Medical had approximately $210 million in cash, including restricted cash, cash equivalents and short-term investments.

How much did Outset Medical's (OM) operating expenses decrease in Q4 2024?

Operating expenses declined 28% year-over-year in Q4 2024, reaching $32.6 million compared to $45.1 million in Q4 2023.

What was Outset Medical's (OM) Tablo installed base growth in 2024?

The Tablo installed base grew 10% in 2024, reaching nearly 6,000 consoles.